Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

UnitedHealth Shifts Coverage Plan to Focus on Select Biosimilars

By Ryan Bushey | September 26, 2016

Ken Wolter / Shutterstock.com

UnitedHealth Group is joining the ranks of insurers opting to prioritize cheaper versions of drugs over their name-brand counterparts.

A bulletin sent to customers seeking client feedback explained the nation’s largest insurer will be changing its reimbursement terms for drugs like long-acting insulins, reported Reuters.  

Sanofi’s Lantus will no longer be a part of the coverage plan. UnitedHealth will instead switch it with Eli Lilly’s biosimilar insulin Basaglar. Novo Nordisk’s Levemir was downgraded from a Tier 1 plan to Tier 2.

Another change-up occurred with Amgen. The company’s white-blood cell boosting drug Neupogen won’t be part of the coverage plan next year. Novartis’ biosimilar Zarxio will be its replacement, but the Swiss drug maker will see its leukemia therapy Gleevec be removed from this list and have the generic version made by Sun Pharma rise in its place.

It’s not all bad news for some of the pharmaceutical firms.

“Some drugs–such as multiple sclerosis treatments from Novartis, Sanofi and Biogen–will get a boost. Seven MS drugs that were previously excluded–as was Biogen’s Plegridy–or otherwise restricted will be freely available. These include Biogen’s Tecfidera, Novartis’ Gilenya and Sanofi’s Aubagio, three of the new generation of oral treatments,” wrote FierceBiotech.

Plus, UnitedHealth will take a proactive step in changing coverage plans based on trends like overprescribing. As an example, it changed its pain-drug coverage by dropping Purdue’s OxyContin and two other opioids in order to adhere to new CDC guidelines while also contending with an increase in pharmaceutical advertising.

This revamp is part of a growing trend. CVS Health and Express Scripts both changed their formularies to include the most cost-effective options for patients as drug prices continue to rise. Healthcare systems in the U.S. and Europe could save billions over the next few years by adopting these cheap medications into health plans.

UnitedHealth’s updated formulary will go into effect next year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE